ArticleFrontiers in endocrinology2025
Gut microbiota dysbiosis affects the local renin-angiotensin system to induce osteoporosis.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The gut microbiota has been found to play a key role in bone metabolism, and renin-angiotensin components are locally expressed in bones and affect bone metabolism, but the link between the two is still unclear. This study aims to investigate whether gut microbiota dysbiosis causes osteoporosis through local renin-angiotensin system (RAS). Methods: Osteoporosis was induced in mice by long-term antibiotic feeding, which disrupted their gut microbiota. Subsequently, the role of RAS in this process was investigated by modulating angiotensin II receptor activity. Results: Long-term antibiotic treatment leads to significant alterations in gut microbiota and leads to osteoporosis, and that localized RAS in bone tissue promotes osteoclast proliferation and activity through up-regulation of ERK1/2 to promote RANKL release and inflammatory infiltration, leading to osteoporosis, and that the angiotensin II Type 2 Receptor (AT2R) may be an important target for this process. Conclusions: Dysbiosis of the gut microbiota leads to osteoporosis by enhancing the activity of the local renin-angiotensin system in bones. Upregulation of ERK1/2 and RANKL, along with inflammatory responses, collectively drive bone loss. AT2R may be a potential therapeutic target. These findings highlight the role of the gut-bone axis and suggest that targeted therapeutic approaches should be further investigated.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.